SingaporeTuberculosis profile
Population  2016 5.6 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.051 (0.044–0.058) 0.91 (0.79–1)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.12 (0.08–0.17)
Incidence  (includes HIV+TB) 2.8 (2.4–3.3) 51 (43–58)
Incidence (HIV+TB only) 0.044 (0.037–0.051) 0.78 (0.66–0.9)
Incidence (MDR/RR-TB)** 0.051 (0.031–0.071) 0.91 (0.55–1.3)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.13 (0.11–0.15) 1 (0.86–1.2) 1.1 (0.97–1.3)
Males 0.15 (0.12–0.17) 1.5 (1.3–1.8) 1.7 (1.4–1.9)
Total 0.27 (0.23–0.32) 2.6 (2.2–2.9) 2.8 (2.4–3.3)
TB case notifications, 2016  
Total cases notified 2 473
Total new and relapse 2 469
          - % tested with rapid diagnostics at time of diagnosis 44%
          - % with known HIV status 88%
          - % pulmonary 84%
          - % bacteriologically confirmed among pulmonary 64%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.02 (0.02–0.03)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 35 2%
          - on antiretroviral therapy    
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  31
(17–44)
Estimated % of TB cases with MDR/RR-TB 1.4% (0.83–2.3) 2.3% (0.28–8.1)  
% notified tested for rifampicin resistance 61% 64% 1 515
MDR/RR-TB cases tested for resistance to second-line drugs   23
Laboratory-confirmed cases MDR/RR-TB: 23, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 19, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 79% 2 143
Previously treated cases, excluding relapse, registered in 2015 100% 5
HIV-positive TB cases registered in 2015 82% 34
MDR/RR-TB cases started on second-line treatment in 2014 50% 14
XDR-TB cases started on second-line treatment in 2014 100% 1
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2017  
National TB budget (US$ millions) 9.8
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-19 Data: www.who.int/tb/data